Tobira Therapeutics Acquired By Allergan For $1.7B
San Francisco-based Tobira therapeutics, a publicly held biopharmaceuticals firm developing threapy to treat liver disease, has been acquired by Allergan, in a deal worth $1.695 billion. Allergan said it will pay $28.35 per share in cash, and up to $49.84 per share in earn out, for Tobira. Tobira trades on the NASDAQ as TBRA. Tobira is commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. Allergan is based in Dublin, Ireland.
posted on Tuesday, September 20, 2016
Related companies:
Tobira Therapeutics
Related stories:
> MAP Pharmaceuticals Acquired By Allergan
> Oculeve Acquired By Allergan For $125M
> ZELTIQ Acquired By Allergan For $2.47 Billion
> Pearl Therapeutics Acquired For $1.15 Billion
> Canaan Partners Raises $675M Fund
silicontap.com Home